{
    "clinical_study": {
        "@rank": "50108", 
        "acronym": "Nunavik2", 
        "arm_group": {
            "arm_group_label": "2006-2010 cohort", 
            "description": "cohort of children born between 2006 and 2010, and living in  Nunavik"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to document the residual burden of acute upper respiratory\n      infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and\n      auditory functional and anatomical abnormalities in children under the age of 5 years in\n      Nunavik who will be exposed to PHiD-CV in combination with PCV-7 or PCV-13.  The comparison\n      groups will be the cohorts of children who received no PCV vaccine (those born in 1994-1996)\n      and those exposed to PCV-7 exclusively (those born in 2003-2007)."
        }, 
        "brief_title": "Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Upper Respiratory Infection", 
            "Acute Lower Respiratory Tract Infection", 
            "Otitis Media (OM)", 
            "Invasive Pneumococcal Disease, Protection Against"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Otitis", 
                "Otitis Media", 
                "Respiratory Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Around 1420 children born between 2006 and 2010 had been eligible to routine immunization\n      program with pneumococcal vaccines.\n\n      The objective of this study is to document the residual burden of acute upper respiratory\n      infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and\n      auditory functional and anatomical abnormalities in children under the age of 5 years in\n      Nunavik who will be exposed to PHiD-CV in combination with PCV-7 or PCV-13.  The comparison\n      groups will be the cohorts of children who received no PCV vaccine (those born in 1994-1996)\n      and those exposed to PCV-7 exclusively (those born in 2003-2007).\n\n      The specific objectives are to measure in children under the age of 5 years in Nunavik and\n      born in the period 2009 to 2010:\n\n        1. the incidence of invasive pneumococcal disease(IPD), AURIs, ALRIs and OMs;\n\n        2. the frequency of antibiotic treatments due to these diseases;\n\n        3. the frequency of hospitalizations and transfers to the South on account of ALRIs;\n\n        4. the frequency of tympanotomies and ventilation tube insertions;\n\n        5. the prevalence of anatomical and functional lesions of the middle ear at the age of 5\n           years (the main issue).\n\n      The main research hypothesis is that the incidence of AURIs, ALRIs and OMs and the\n      prevalence of sequelae from OM decreased after the implementation of PHiD-CV in 2009, as\n      compared with previous cohorts of children who were not exposed to this new vaccine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Born between 2006 and 2010\n\n          -  Resident in Nunavik (province of Quebec, Canada)\n\n        Exclusion Criteria:\n\n        \u2022     Not applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "5 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Children of Nunavik born between 2006 and 2010, who have been exposed to PHiD-CV in\n        combination with PCV-7 or PCV-13"
            }
        }, 
        "enrollment": {
            "#text": "1420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694329", 
            "org_study_id": "GSK114180"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Streptococcus pneumoniae", 
            "Pneumococcal Conjugate Vaccines", 
            "Immunization", 
            "Otitis media"
        ], 
        "lastchanged_date": "September 25, 2012", 
        "location": {
            "contact": {
                "email": "martine.six@ssss.gouv.qc.ca", 
                "last_name": "Philippe De Wals, MD PhD", 
                "phone": "418-666-7000", 
                "phone_ext": "363"
            }, 
            "facility": {
                "address": {
                    "city": "Quebec City", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "G1R 3L5"
                }, 
                "name": "Centre de recherche du CHUQ"
            }, 
            "investigator": [
                {
                    "last_name": "Philippe De Wals, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jean-Fran\u00e7ois Proulx, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada", 
        "overall_official": {
            "affiliation": "Centre de recherche du CHUQ", 
            "last_name": "Philippe De Wals, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prevalence of anatomical and functional lesions of the middle ear at the age of 5 years.", 
            "safety_issue": "No", 
            "time_frame": "at age of 5 years old"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of IPDs", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Frequency of antibiotic treatments due to diseases of interest", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Frequency of hospitalizations and transfers to the South on account of ALRIs", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Frequency of tympanotomies and ventilation tube insertions", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Incidence of AURIs", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Incidence of ALRIs", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }, 
            {
                "measure": "Incidence of OMs", 
                "safety_issue": "No", 
                "time_frame": "at age of 5 years old"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}